| Popis: |
Introduction. Preeclampsia affects approximately 4.6% of pregnancies worldwide. In 2018, ACOG updated their low dose aspirin (LDA) supplementation recommendation to include pregnant women at moderate risk for preeclampsia. In addition to the potential benefit of LDA supplementation for delaying or preventing preeclampsia, LDA supplementation can affect neonatal outcomes. We study the association of LDA supplementation with six neonatal outcomes: length of stay (LOS) in hospital, NICU admission, hospital readmission, birth weight (BW), one-minute Apgar score, and five-minute Apgar score in a sample of mostly minority pregnant women from Hispanic and Black race/ethnicities. Methods. This was a retrospective study of 634 patients from January 2018 through April 2021.Our main predictor variable was maternal LDA supplementation on 6 neonatal outcomes: NICU admission, neonatal readmission, one and five minute Apgar scores, neonatal BW and hospital LOS. We adjusted for demographics, comorbidities and maternal high- or moderate-risk designation per ACOG guidelines. Results. We found that high-risk designation was associated with neonatal increased rate of NICU admission (OR: 3.80, 95% CI: 2.02, 7.13, p |
